Synairgen phase 3 trial results. In October 2021 Synairgen announced that SNG001 had .

Synairgen phase 3 trial results Nov 12, 2021 · Synairgen noted that the top-line results from the trial are anticipated early next year. During the trial, in version 3 of the protocol, the Nov 11, 2021 · Synairgen's SG018 Phase 3 trial is a randomised, double-blind, placebo-controlled study being conducted in 17 countries. Nov 11, 2021 · Level the playing field with access to the latest investment research. I look forward to the readout of results in the near future Apr 30, 2021 · In parallel with the Phase III trial in the hospital setting, there is now an urgent need to assess SNG001 in the non-hospital Synairgen announced the results of its Phase II double-blind Oct 4, 2022 · Based on the study results, the Independent Data Safety Monitoring Board for ACTIV-2 recommended SNG001 advance from Phase 2 into Phase 3 in the ACTIV-2 trial in October 2021. SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation – INF-beta is a naturally occurring protein that controls Jan 14, 2021 · The trials of Synairgen's inhaled drug as a treatment for COVID-19 are going global. Synairgen began a placebo-controlled Phase 2 trial in COVID-19 patients in the UK in March 2020. Last trade - 00:00. Southampton, UK – 26 September 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the immunomodulatory broad-spectrum antiviral protein interferon beta Feb 21, 2022 · Synairgen plc ('Synairgen' or the 'Company') Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19 Feb 21, 2022 · Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19 Institute of Health's ACTIV-2 trial. 1. Feb 21, 2022 · Synairgen plc announced that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. 1% after announcing the phase 3 clinical trial results of its SNG001 inhaled COVID-19 treatment in hospitalised patients. Southampton, UK - 21 February 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the international Phase 3 SPRINTER trial of SNG001 in patients Apr 5, 2022 · The SPRINTER trial (SG018; NCT04732949) was a global Phase 3, randomised, placebo-controlled, double-blind, multi-site clinical trial assessing the efficacy and safety of inhaled SNG001 on top of standard of care for the treatment of adults hospitalised due to COVID-19 requiring treatment with supplemental oxygen by mask or nasal prongs. Randomized controlled trials of subcutaneous IFN-β in hospitalized participants showed clinical benefit in some but not all studies. Richard Marsden, CEO of Synairgen, commented: "Conducting clinical trials in the time of COVID-19 is challenging but as important now as at the start of SNG — Synairgen News Story. 19–22 Nebulized inhaled IFN-β (SNG001) was shown to be beneficial for hospitalized COVID-19 patients in a Phase 2 study, 23 and has Dec 23, 2022 · StockReports™ Analyse your stocks in seconds Stock Research Expert insight you can understand; StockRanks™ Identify winning stocks Screeners Generate investing ideas fast May 24, 2021 · Press release. The EU Clinical Trials Register currently displays 44307 clinical trials with a EudraCT protocol, of which 7355 are clinical trials conducted with subjects less than 18 years old. tranScrip is delighted with the initiation of dosing in Synairgen’s international Phase III trial (SG018) of inhaled interferon beta in hospitalised COVID-19 patients. Equity research, broker reports, and media content available to private and non-institutional investors. Oct 23, 2024 · In April 2024, Amgen (NASDAQ: AMGN) shared an update on the Phase 2a COURSE trial results for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which will be presented at the American Thoracic Society (ATS) 2024 International Conference. Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID Oct 20, 2021 · In addition to the ACTIV-2 trial, our own Phase III SPRINTER study assessing SNG001 in hospitalised COVID-19 patients, is also progressing well and we expect top-line results Synairgen’s May 24, 2021 · Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants Mar 17, 2022 · SNG001 was included in this study in February 2021 and the Independent Data Safety Monitoring Board for ACTIV-2 had previously (October 2021) recommended it advance from Phase 2 into Phase 3. Upon successful completion of the Phase III study, the company plans to file an emergency use authorization application with the US Food and Drug Administration (FDA) to treat Covid-19 patients who require hospitalisation. There was, however, an encouraging signal in reduction in the relative risk (RRR) of progression to severe disease or death within 35 days (25. 2. Mar 3, 2022 · Southampton, UK - 03 March 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces an update on SNG001 in the ACTIV-2 Phase 3 trial for COVID-19 and on SNG001 activity against Delta and Omicron variants. Synairgen plc. The results have not been published in a peer-reviewed journal, nor has the full data been made Oct 20, 2021 · In addition to the ACTIV-2 trial, our own Phase III SPRINTER study assessing SNG001 in hospitalised COVID-19 patients, is also progressing well and we expect top-line results in early 2022. In July 2020, Synairgen announced SNG001 lowered the risk of severe COVID-19 in infected patients in a small clinical trial. tranScrip has provided a range of specialist support services to Synairgen for over 10 years and has been involved in the COVID-19 programme since the beginning. Well, the short answer is Synairgen Share Price Ends the Week Up 451% – Should You Buy It? May 16, 2022 · Synairgen announced in February 2022 that the Phase 3 SPRINTER trial did not meet the primary endpoints of discharge from hospital and recovery. Richard Marsden, CEO of Synairgen, commented: "While we are disappointed by the overall outcome, SNG 001 has been administered to hospitalised patients on top of standard of care which changed substantially between our Phase II and Phase III trials. CQycsQUoq3nYhmWv9pMpm-P5L8gPQj89qCtsPZnh8Xc. The biotech company’s valuation was justified by its ongoing phase III trial into its novel ‘SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon Oct 20, 2021 · Has no revenue either year, but research and development spending is reduced to GBP3. Investors reacted negatively to news that SNG001 failed to meet its primary and secondary endpoints during the phase 3 clinical trial on hospitalised patients. Download as PDF. Feb 21, 2022 · Synairgen plc Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19 Southampton, UK- Jan 14, 2021 · The trials of Synairgen's inhaled drug as a treatment for COVID-19 are going global. 1 million) as expenditure on the Phase 3 SPRINTER trial, substantially completed in 2022, decreased and manufacturing activities reduced. Positive results from this would mark a major breakthrough in the treatment of COVID-19, and a transitional milestone for Synairgen. Jan 13, 2021 · Press release. SNG001 demonstrated Feb 21, 2022 · Synairgen PLC (AIM:SNG, OTC:SYGGF) said its treatment for Covid failed to meet both its primary and secondary goals in a phase III clinical trial. May 16, 2022 · Synairgen plc announces the first presentation of the full data analysis from its Phase 3 SPRINTER trial evaluating the efficacy and safety of SNG001 in patients hospitalised with COVID-19. Richard Marsden, CEO of Synairgen, from the Phase 3 SPRINTER trial showed an encouraging Dec 31, 2023 · ('Synairgen' or the 'Company') Results for the year ended 31 December 2023 which is to conduct a Phase 2 trial in mechanically ventilated patients where there is a substantial unmet medical Jun 27, 2024 · TRADING UPDATES: SulNOx raises funds; Synairgen shares trial results 22-12-23: AN Synairgen plc Announces the Online Publication of Data from Its Phase 3 Sprinter Trial in the Peer Reviewed European Respiratory Journal Open Research 22-12-23: CI Explore Synairgen Research Ltd staff directory for direct access to contact details on 24 employees including email format, email address and phone numbers. 5 million from GBP11. Synairgen plc the respiratory drug discovery and development company, has announced that the first patient has been dosed in the UK as part of its global Phase III trial (SG018) evaluating Synairgen’s inhaled formulation of interferon beta-1a (SNG001), for the treatment of hospitalised COVID-19 patients. Feb 15, 2021 · In July 2020, Synairgen announced the results of its Phase II double-blind, placebo-controlled study of 101 randomised COVID-19 hospitalised patients, which showed that SNG001 given for 14 days Feb 21, 2022 · Synairgen plc Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19 Southampton, UK- Feb 23, 2022 · SNG 001 demonstrated a favourable safety profile and was well tolerated in this population. Based on the results of the Phase 2 trial, the company initiated a Phase 3 trial in January 2021 which ultimately included 17 countries. Oct 21, 2020 · ec8c765dc1. All Rights ReservedRegistered in England and Wales No. May 3, 2021 · Synairgen has reported that results from the home cohort of its SG016 Phase II clinical trial of inhaled SNG001 demonstrated a reduction in the rate of hospitalisation in Covid-19 patients. Feb 22, 2022 · Synairgen’s time riding the COVID-19 wave has come crashing to a close. Dec 31, 2022 · In October 2022, Synairgen received the positive topline results for outcomes through 28 days of follow-up from the Phase 2 evaluation of SNG001 from the US National Institute of Allergy and Infectious Diseases (NIAID) ACTIV-2 trial (Protocol ACTIV-2/A5401: “Adaptive Platform Treatment Trial for Outpatients with COVID-19 [Adapt out COVID Nov 12, 2020 · We did a randomised, double-blind, placebo-controlled, phase 2 pilot trial at nine UK sites. 66p down to 111. Market Cap. Exclusion criteria included inability to use a nebuliser with a mouthpiece (eg, ventilated patients and patients in intensive care); and pregnancy or intention to become pregnant and breastfeeding (a complete list of inclusion and exclusion criteria is provided in the appendix pp 2–3). gov and the data presented are from a revised phase II trial in 100 patients hospitalised with COVID-19. Feb 21, 2022 · The Synairgen plc (LON: SNG) share price crashed 92. Level the playing field with access to the latest investment research. Synairgen plc (‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2024. Its inhaled interferon beta candidate SNG001 posted a clean sweep of failures against key endpoints in a phase 3 clinical © Synairgen plc. £5. Feb 23, 2022 · SNG001 was also found to have a favourable safety profile and was well tolerated in the trial subjects. Synairgen CEO Richard Marsden said: “While we are disappointed by the overall outcome, SNG001 has been administered to hospitalised patients on top of standard of care which changed substantially between our Phase II and Phase III trials. Adults aged 18 years or older and admitted to hospital with COVID-19 symptoms, with a positive RT-PCR or point-of-care test, or both, were randomly assigned (1:1) to receive SNG001 (6 MIU) or placebo by inhalation via a mouthpiece daily for 14 days. Synairgen plc Announces the Online Publication of Data from Its Phase 3 Sprinter Trial in the Peer Reviewed European Respiratory Journal Open Research Dec 24 Synairgen plc Appoints Amanda Radford FCA to the Board as an Independent Non-Executive Director and Chair of the Audit Committee Feb 21, 2022 · Synairgen plc announced that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. The topline data from Synairgen's Phase 3 clinical programme evaluating SNG001 Dec 3, 2021 · The Phase III trial by Synairgen is recruiting patients who require oxygen therapy via nasal prongs or mask. Shares nevertheless took a tumble after the announcement on 30 April, falling more than 25% from 150. Mar 22, 2021 · Shares of British biotech company Synairgen ended the week up 451% and you might be wondering if its a good time to buy the stock. 2%]. 6%] and nine on placebo [8. 5 million (30 June 2022: £11. SNG001 Synairgen plc Announces the Online Publication of Data from Its Phase 3 Sprinter Trial in the Peer Reviewed European Respiratory Journal Open Research Dec 24 Synairgen plc Appoints Amanda Radford FCA to the Board as an Independent Non-Executive Director and Chair of the Audit Committee Jan 13, 2021 · Southampton, UK - 13 January 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that the first patient has been dosed in the UK as part of its global Phase III trial (SG018) evaluating Synairgen's inhaled formulation of interferon beta-1a (SNG001), for the treatment of hospitalised COVID-19 Jan 22, 2021 · We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. c17f1URh6QOx_wfLoqRY2bqReq87cnpJ93ogELSUhxRIR-30Xxn6Mej8Dg Jan 22, 2021 · We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. 00%. Clinical trials of IFN therapeutics for COVID-19 have produced mixed results. Oct 4, 2022 · There were 13 participants with treatment-emergent Grade 3 or higher Adverse Events (AE) with four on SNG001 [3. 5233429 | Site by EtherRegistered in England and Wales No. Southampton, UK - 23 December 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the online publication Dec 31, 2021 · In March 2022, due to the need to modify the study design in light of the emergence of the Omicron variant of SARS-CoV-2, the US National Institutes of Health (NIH) ACTIV-2 trial team asked Synairgen to temporarily pause preparation activities for ACTIV-2 Phase 3 until the timeline for the activation of SNG001 in the trial could be clarified. The inhaled Jun 30, 2022 · Research and development expenditure for the six months ended 30 June 2023 was £3. Jun 30, 2023 · RNS Number : 7084F. 26 September 2024. May 16, 2022 · The SPRINTER trial (SG018; NCT04732949) was a global Phase 3, randomised, placebo-controlled, double-blind, clinical trial assessing the efficacy and safety of inhaled SNG001 on top of standard of Feb 21, 2022 · Synairgen plc announced that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. Feb 21, 2022 · Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19. SNG001 did not materially shorten hospital stay Dec 23, 2022 · Synairgen plc 23 December 2022 Synairgen plc ('Synairgen' or the 'Company') Results from SPRINTER Phase 3 trial Oct 4, 2022 · There were 13 participants with treatment-emergent Grade 3 or higher Adverse Events (AE) with four on SNG001 [3. 49p 0. Southampton, UK - 23 December 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the online publication Sep 30, 2021 · Synairgen is focused on completing its 610 patient Phase III SPRINTER trial with top line data expected in early 2022. they are by definition more likely to have marked or severe Jul 20, 2020 · Stock market rules mean Synairgen is obliged to report the preliminary results of the trial. In October 2021 Synairgen announced that SNG001 had May 11, 2021 · Small cap respiratory drug developer Synairgen LON:SNG has reported positive results from its phase II clinical trial of inhaled SNG001 in Sars-CoV-2 infected patients. 7% 1 reduction in the Intention-to-Treat population and 36 Nov 13, 2020 · Southampton, UK-based biotech company Synairgen has announced that a small phase 2 trial of its investigational candidate SNG001 supports advancement into phase 3 testing. 7% [1] reduction in the Intention-to-Treat population and Dec 31, 2022 · Richard Marsden, CEO of Synairgen, said: “We are pleased to have selected an exciting path forward for SNG001, which is to conduct a Phase 2 trial in mechanically ventilated patients where there is a substantial unmet medical need with 25% to 45% mortality and few antiviral therapeutic options. Once the final patients have completed the initial 35-day trial period, quality assurance and statistical analysis will be completed. Synairgen share price: trials and tribulations. Apr 5, 2022 · The session is a platform for important trial results that are novel and represent important new understanding. Healthcare Highly Speculative Micro Cap Sucker Stock. Data from the phase 3 trial could provide a much-needed tiebreaker on the efficacy of the treatment, which so far has had a mixed bag Oct 20, 2021 · Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2COVID-19 Trial Southampton, UK - 20 October 2021: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad- spectrum anti-viral protein interferon beta (IFN-beta) for the treatment of severe viral lung infections, has been Sep 20, 2022 · The SPRINTER trial (SG018; NCT04732949) was a global Phase 3, randomised, placebo-controlled, double-blind, clinical trial assessing the efficacy and safety of inhaled SNG001 on top of standard of care (SOC) for the treatment of adults hospitalised due to COVID-19 requiring treatment with supplemental oxygen by mask or nasal prongs. Based on the study results, the Independent Data Safety Monitoring Board for ACTIV-2 recommended SNG001 advance from Phase 2 into Phase 3 in the ACTIV-2 trial in October 2021. 1 million, as phase 3 Sprinter trial of SNG001 is mostly completed in 2022. Tom Wilkinson, Chief Investigator and Professor of Respiratory Medicine, University of Southampton, said: "The results of the SPRINTER study confirm that inhaled interferon beta can be Dec 23, 2022 · Synairgen plc ('Synairgen' or the 'Company') Results from SPRINTER Phase 3 trial published in the European Respiratory Journal Open Research. Feb 21, 2022 · In October 2021 Synairgen announced that SNG001 had been recommended to advance from Phase 2 into Phase 3 in this trial in mild to moderate COVID-19 patients. 05m. Mar 16, 2022 · The trial will be conducted by the AIDS Clinical Trials Group. In July 2020, Synairgen announced positive results from a Phase 2 trial of SNG001 in COVID-19 patients hospitalized in the UK. . SNG001 is a formulation with inhaled interferon beta (IFN-beta) for nebulisation, enabling its direct delivery into the lungs of the patients. Jul 20, 2020 · “Synairgen have released the first analysis of the SG016 trial of inhaled interferon-beta-1a (SNG001) in patients in a press release this morning. 90p on 4 Feb 21, 2022 · Level the playing field with access to the latest investment research. ” As of today, Synairgen has not received any data from the ACTIV-2 trial. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006). Alongside this, we have continued our work as Dec 23, 2022 · Synairgen plc ('Synairgen' or the 'Company') Results from SPRINTER Phase 3 trial published in the European Respiratory Journal Open Research Southampton, UK - 23 December 2022: Synairgen plc (LSE In March 2020, [13] Synairgen initiated a placebo-controlled Phase 2 trial of SNG001, an inhaled form of interferon beta, in COVID-19 patients in the UK. Adults aged 18 years or older and admitted to hospital with COVID-19 symptoms, with a positive RT-PCR or point-of-care test, or both, were randomly assigned (1:1) to receive SNG001 (6 MIU) or placebo by inhalation via a mouthpiece daily for 14 Oct 20, 2020 · In July, Synairgen reported positive results from its Phase II trial of 101 hospitalized COVID-19 patients, and an interim analysis of safety, biomarker and efficacy data from their Phase II COPD Synairgen plc ('Synairgen' or the 'Company') Results from SPRINTER Phase 3 trial published in the European Respiratory Journal Open Research. Jul 31, 2020 · SNG001 phase 2 results have proved Synairgen to be an agile company who could quickly progress through trials with an intelligent and well driven management team providing a big boost in this Jun 30, 2022 · · Conducted a post hoc analysis of the Phase 3 SPRINTER trial which showed stronger treatment effects with SNG001 in high-risk patient sub-groups, with the strongest effect observed in those who had clinical signs of compromised respiratory function. In these patients, who represented approximately one-third of the SPRINTER trial population Jan 14, 2021 · UK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19 patients, after encouraging topline results from a phase 2 study that started last March. e. Feb 21, 2022 · Synairgen PLC (AIM:SNG, OTC:SYGGF) said its treatment for Covid failed to meet both its primary and secondary goals in a phase III clinical trial. The trial, which investigated tezepelumab in patients with moderate to very Feb 21, 2022 · Synairgen plc Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19 Southampton, UK- Nov 11, 2021 · Synairgen’s SG018 Phase 3 trial is a randomised, double-blind, placebo-controlled study being conducted in 17 countries. Enterprise Value-£3 Mar 17, 2022 · Blackbird’s Ian McDonough discusses FY24 results with +ve EBITDA & Future Plans 2 into Phase 3. Synairgen reported in February this year that the international Phase III trial of SNG001 in Covid-19 patients admitted to the hospital failed to meet the primary or secondary efficacy endpoints. Synairgen plc Announces the Online Publication of Data from Its Phase 3 Sprinter Trial in the Peer Reviewed European Respiratory Journal Open Research Dec 24 Synairgen plc Appoints Amanda Radford FCA to the Board as an Independent Non-Executive Director and Chair of the Audit Committee Feb 22, 2022 · However, Synairgen shares have now recovered to 26p, as a home-based trial could still yield results. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. 00 0. Synairgen announced in February 2022 that the Phase 3 SPRINTER trial did not meet the primary endpoints of discharge from hospital and recovery. Credit: Shutterstock The ideal administration timing for the Phase III Synairgen nebulised SNG001 (interferon beta-1a) asset may prove challenging to evoke the best efficacy and safety in hospitalised Covid-19, experts say. Apr 5, 2022 · Synairgen plc, the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that further analysis of its Phase 3 SPRINTER trial data will be presented at the ATS 2022 International Conference, being held between 13-18 May 2022 in San Francisco. Oct 20, 2021 · Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Southampton, UK Dec 23, 2022 · Synairgen PLC - Southampton, England-based respiratory company developing SNG001 treatment, containing the broad-spectrum antiviral protein interferon beta - Publishes results of Sprinter phase 3 Methods: We did a randomised, double-blind, placebo-controlled, phase 2 pilot trial at nine UK sites. . Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants Jun 8, 2024 · TIDMSNG RNS Number : 2097C Synairgen plc 21 February 2022 Synairgen plc ('Synairgen' or the 'Company') Synairgen announces topline results from Phase 3 SPRI Nov 6, 2024 · Synairgen plc ('Synairgen' or the 'Company') £18 million raised to fund Phase 2 INVENT clinical trial of SNG001 in ventilated patients with severe viral lung infections Feb 21, 2022 · Synairgen plc 21 February 2022 Synairgen plc ('Synairgen' or the 'Company') Synairgen announces topline results Nov 24, 2020 · Parexel announced that Synairgen has signed a collaboration agreement with Parexel Biotech for a Phase 3 trial of Synairgen’s SNG001 nebulized interferon-beta-1a for the treatment of COVID-19. The details of the study were published in Lancet in November 2020 Feb 21, 2022 · Synairgen plc Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19 Mar 4, 2022 · Synairgen and its clinical advisors believe that the data warrants additional analysis in a platform trial, which the company is currently studying. Mar 24, 2025 · COVID-19 Phase III trial – SG018 Synairgen’s global Phase III “SPRINTER” clinical trial in hospitalized COVID-19 patients, SG018, is a randomised, placebo-controlled study being conducted in 17 countries enrolling a total of 610 COVID-19 patients who require supplemental oxygen (ie they are by definition more likely to have marked or Nov 11, 2021 · Synairgen's SG018 Phase 3 trial is a randomised, double-blind, placebo-controlled study being conducted in 17 countries. 5233429 | Site by Ether SNG Synairgen Plc Synairgen plc Topline results from Phase 3 SPRINTER trial (2097C) TIDMSNG RNS Number : 2097C Synairgen plc 21 February 2022 Synairgen plc ('Synairgen' or the 'Company') Synairgen Jan 13, 2021 · Synairgen has announced that the first patient has been dosed in the UK a part of a global Phase III trial evaluating the inhaled formulation of interferon beta-1a , for the treatment of hospitalised May 25, 2021 · COVID-19 Phase III trial - SG018 Synairgen's global Phase III "SPRINTER" clinical trial in hospitalised COVID-19 patients, SG018, is a randomised, placebo-controlled study being conducted in 17 countries enrolling a total of 610 COVID-19 patients who require supplemental oxygen (i. The trial design has changed from that published on clinicaltrials. crc kbhv jrgtn xldd hgvpzyko eiq gdtls jrbltg hftvpt ykurxh loe pumit flxj zssqg mclvve